Systematic review of economic evaluation studies of drug-based non-malignant chronic pain treatment.

@article{Backhaus2019SystematicRO,
  title={Systematic review of economic evaluation studies of drug-based non-malignant chronic pain treatment.},
  author={Insa Backhaus and Alice Mannocci and Giuseppe La Torre},
  journal={Current pharmaceutical biotechnology},
  year={2019}
}
BACKGROUND AND OBJECTIVE Chronic pain is a highly prevalent problem, involving high costs and seriously affecting a patient's quality of life. This review aimed to systematically review economic evaluations of pharmacological-based treatments for non-malignant chronic pain and to compare different treatment approaches with regard to their economic profile. METHODS PubMed and Scopus were systematically searched in April 2016. Studies were included if quality-adjusted life years and incremental… 
2 Citations
The efficacy of extracorporeal shock wave for chronic musculoskeletal pain conditions
TLDR
This systematic review is the first to assess the effectiveness and safety of extracorporeal shock-wave therapy (ESWT) for patients with chronic musculoskeletal pain conditions and can provide the updated evidence which is of great importance for patients, clinical practice and health related policy maker in ESWT treating CMPC.
The efficacy of extracorp oreal shock wave for chronic musculoskeletal pain conditions A protocol of systematic review and meta-analysis of randomized controlled trials
  • 2020

References

SHOWING 1-10 OF 46 REFERENCES
Epidemiology of chronic non-cancer pain in Europe: narrative review of prevalence, pain treatments and pain impact
TLDR
It is clear that chronic pain has a dramatic impact on European society and the lack of data in this area clearly underlines the need for decision makers in healthcare to gather further epidemiological data.
Economic evaluation in chronic pain: a systematic review and de novo flexible economic model
TLDR
It is vital that future economic models in chronic pain are designed to be fully transparent and hope the open-source code is useful in order to aspire to a common approach to modelling pain that includes robust sensitivity analyses to test structural and parameter uncertainty.
Pharmacological Management of Chronic Lower Back Pain: A Review of Cost Effectiveness
TLDR
Future economic evaluations of interventions for chronic lower back pain, including pharmacological interventions, should be based on the results of well-conducted RCTs where the measurement of costs and outcomes such as quality of life and quality-adjusted life-years is included in the trial protocol, and which have a follow-up period sufficient to capture meaningful changes in both costs and outcome.
The cost-effectiveness of duloxetine in chronic low back pain: a US private payer perspective.
Cost-effectiveness of ziconotide in intrathecal pain management for severe chronic pain patients in the UK
TLDR
Ziconotide may offer an economically feasible alternative solution for patients for whom current treatment is inappropriate or ineffective and should be considered as a treatment for severe chronic pain.
Clinical Effectiveness and Cost-Effectiveness of Treatments for Patients With Chronic Pain
  • D. Turk
  • Medicine
    The Clinical journal of pain
  • 2002
TLDR
Pain rehabilitation programs provide comparable reduction in pain to alternative pain treatment modalities, but with significantly better outcomes for medication use, health care utilization, functional activities, return to work, closure of disability claims, and with substantially fewer iatrogenic consequences and adverse events.
Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany
TLDR
Transdermal fentanyl is cost-effective compared to both sustained-release morphine and CO and dominant compared to transdermal buprenorphine in the treatment of adults with nonmalignant moderate to severe chronic pain.
Cost-effectiveness analysis of pregabalin for treatment of chronic low back pain in patients with accompanying lower limb pain (neuropathic component) in Japan
TLDR
Using data and assumptions from routine clinical practice, pregabalin is cost-effective for the treatment of CLBP-NeP in Japan.
...
...